Jürgen Bader

936 total citations
15 papers, 670 citations indexed

About

Jürgen Bader is a scholar working on Molecular Biology, Hematology and Infectious Diseases. According to data from OpenAlex, Jürgen Bader has authored 15 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Hematology and 4 papers in Infectious Diseases. Recurrent topics in Jürgen Bader's work include Multiple Myeloma Research and Treatments (7 papers), Ubiquitin and proteasome pathways (5 papers) and Receptor Mechanisms and Signaling (4 papers). Jürgen Bader is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Ubiquitin and proteasome pathways (5 papers) and Receptor Mechanisms and Signaling (4 papers). Jürgen Bader collaborates with scholars based in Switzerland, Netherlands and Germany. Jürgen Bader's co-authors include Christoph Driessen, Marianne Kraus, Herman S. Overkleeft, Annette G. Beck‐Sickinger, Michaela C. Dinger, A. Kretzschmar, Gerd Folkers, Peter J. A. Weber, Gerjan de Bruin and Lenka Bešše and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Annals of Oncology.

In The Last Decade

Jürgen Bader

15 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jürgen Bader Switzerland 10 551 243 157 104 61 15 670
Sandrine Curtet France 12 1.5k 2.6× 172 0.7× 268 1.7× 50 0.5× 20 0.3× 14 1.6k
Michael Pranpat United States 6 1.1k 2.0× 252 1.0× 251 1.6× 41 0.4× 22 0.4× 11 1.3k
Eric Kowarz Germany 11 429 0.8× 126 0.5× 81 0.5× 22 0.2× 48 0.8× 24 621
Sandhya Kumaraswamy United States 5 909 1.6× 230 0.9× 203 1.3× 34 0.3× 21 0.3× 9 1.1k
Jayasha Shandilya India 17 658 1.2× 45 0.2× 139 0.9× 33 0.3× 14 0.2× 27 814
Malini Menon India 8 325 0.6× 25 0.1× 153 1.0× 82 0.8× 30 0.5× 10 435
Jean-Marc Navenot United States 11 369 0.7× 45 0.2× 222 1.4× 86 0.8× 35 0.6× 14 627
Nagma Khan United Kingdom 5 702 1.3× 24 0.1× 178 1.1× 44 0.4× 31 0.5× 8 829
Eleanor B. McGowan United States 12 335 0.6× 203 0.8× 52 0.3× 57 0.5× 8 0.1× 18 717
Thomas A. Bacon United States 7 670 1.2× 36 0.1× 81 0.5× 35 0.3× 33 0.5× 9 837

Countries citing papers authored by Jürgen Bader

Since Specialization
Citations

This map shows the geographic impact of Jürgen Bader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen Bader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen Bader more than expected).

Fields of papers citing papers by Jürgen Bader

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen Bader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen Bader. The network helps show where Jürgen Bader may publish in the future.

Co-authorship network of co-authors of Jürgen Bader

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen Bader. A scholar is included among the top collaborators of Jürgen Bader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen Bader. Jürgen Bader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Papadopoulos, Kyriakos P., Afshin Dowlati, Juanita Lopez, et al.. (2024). 650P Initial results from a phase I/II study of BT7480, a novel nectin-4/CD137 bicycle tumor-targeted immune cell agonist, in patients (pts) with advanced solid tumors. Annals of Oncology. 35. S513–S514. 1 indexed citations
2.
Bešše, Andrej, Lenka Bešše, Marianne Kraus, et al.. (2019). Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell chemical biology. 26(3). 340–351.e3. 84 indexed citations
3.
Stolze, Sara Christina, Leo Rasche, Niels Weinhold, et al.. (2017). Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 32(2). 391–401. 87 indexed citations
4.
Li, Nan, Marianne Kraus, Nico J. Meeuwenoord, et al.. (2016). Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 30(11). 2198–2207. 106 indexed citations
5.
Kraus, Marianne, Lenka Bešše, Jürgen Bader, et al.. (2015). The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemotherapy and Pharmacology. 76(2). 383–396. 19 indexed citations
6.
Kraus, Marianne, Jürgen Bader, Paul P. Geurink, et al.. (2015). The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica. 100(10). 1350–1360. 41 indexed citations
7.
8.
Kraus, Marianne, Jürgen Bader, Thomas Mehrling, & Christoph Driessen. (2014). Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro. Blood. 124(21). 2249–2249. 2 indexed citations
9.
Kraus, Marianne, Jürgen Bader, Herman S. Overkleeft, & Christoph Driessen. (2013). Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer Journal. 3(3). e103–e103. 46 indexed citations
10.
11.
12.
Bader, Jürgen & Annette G. Beck‐Sickinger. (2004). Fluorescence Resonance Energy Transfer to Study Receptor Dimerization in Living Cells. Humana Press eBooks. 259. 335–352. 5 indexed citations
13.
Bader, Jürgen, Norman Koglin, Karin Mörl, et al.. (2004). From Transcription Profile to Expression: The Signaling Repertoire of the SK-N-MC Neuroepithelioma Cell-Line. Journal of Receptors and Signal Transduction. 24(4). 257–282. 9 indexed citations
14.
Dinger, Michaela C., et al.. (2003). Homodimerization of Neuropeptide Y Receptors Investigated by Fluorescence Resonance Energy Transfer in Living Cells. Journal of Biological Chemistry. 278(12). 10562–10571. 107 indexed citations
15.
Weber, Peter J. A., Jürgen Bader, Gerd Folkers, & Annette G. Beck‐Sickinger. (1998). A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Bioorganic & Medicinal Chemistry Letters. 8(6). 597–600. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandrine Curtet Breakdown of academic impact, for papers by Michael Pranpat Breakdown of academic impact, for papers by Eric Kowarz Breakdown of academic impact, for papers by Sandhya Kumaraswamy Breakdown of academic impact, for papers by Jayasha Shandilya Breakdown of academic impact, for papers by Malini Menon Breakdown of academic impact, for papers by Jean-Marc Navenot Breakdown of academic impact, for papers by Nagma Khan Breakdown of academic impact, for papers by Eleanor B. McGowan Breakdown of academic impact, for papers by Thomas A. Bacon
Rankless by CCL
2026